Parvovirus B19 screening is an important service provided by plasma centers worldwide.
The virus most commonly causes fifth disease in children but can also cause painful, swollen joints and even severe anemia.1
Roche Molecular offers the cobas® TaqScreen DPX Test and cobas® DPX Test to help manage the B19V burden in plasma pools and identify hepatitis A virus (HAV)-contaminated units. It allows plasma manufacturers to increase processing efficiency and may reduce the number of units that are discarded. The highly precise, quantitative values obtained for B19V DNA, and the test’s high sensitivity for HAV RNA, meet current regulatory requirements for plasma processing.2,3
- Blümel J, Burger R, Drosten C, et al. Parvovirus B19 – Revised. Transfus Med Hemother. 2010;37:339-350.
- U.S. Food and Drug Administration. Guidance for industry: nucleic acid testing (NAT) to reduce the possible risk of human parvovirus B19 transmission by plasma-derived products. 2009 July. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm071592.htm
- Human anti-D immunoglobulin, Monograph 0557 (since 1/1/2004); Human anti-D immunoglobulin for intravenous administration, Monograph 1527 (since 1/1/2004); Human plasma pooled and treated for virus inactivation, Monograph 1646 (since 1/7/2004). Ph. Europe. 6th ed. Strasbourg, France: Council of Europe; 2011.